Records containing: Multiple Myeloma Refractory
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2026-04-22A Phase II, Open-Label, Multicenter Study of Inobrodib in Combination With Pomalidomide and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
-
CLINICAL_TRIALS study record update · 2026-03-17Phase I/II Open-label Study Evaluating The Safety And Efficacy of Anti BCMA CAR-T Cell Therapy in Adults With R/ R Multiple Myeloma
-
CLINICAL_TRIALS study record update · 2026-03-06Phase I Study of Safety and Efficacy of Liposomal Curcumin in Relapsed Refractory Multiple Myeloma
-
CLINICAL_TRIALS study record update · 2026-02-19A Multicenter, Open-label, Single-Arm Phase I/II Clinical Study to Evaluate the Safety and Efficacy of SENL103 Autologous T Cell Injection (S103) in Subjects With Relapsed or Refractory Multiple Myeloma.
-
CLINICAL_TRIALS study record update · 2026-01-07Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell Engager
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2025-10-07A Phase Ib/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Efficacy of HuL001 in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma
-
CLINICAL_TRIALS study record update · 2025-09-29Clinical Study Evaluating the Safety and Efficacy of BCMA/GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma.
-
CLINICAL_TRIALS study record update · 2025-04-03Teclistamab Plus Autologous Lymphocytes Infusion for the Treatment of Relapse/Refractory Multiple Myeloma (TALIM)